Converted by EDGARwiz

[novogendemergertaximplica001.jpg]

21 February 2013

ASX RELEASE

Novogen demerger – tax implications

The demerger of Novogen and MEI Pharma is now complete. IRS Form 8937,

together with a report for all shareholders on the tax implications of the

demerger, are now available on the Novogen website www.novogen.com/

About Novogen

Novogen Ltd is a public Australian biotechnology company whose shares trade

on both the Australian Stock Exchange (symbol ‘NRT’) and NASDAQ (symbol

‘NVGN’). The Company is based in Sydney, Australia and is focused on the

development of a family of novel anti-cancer drugs based on super-benzopyran

and ‘stealth’ drug technologies. The Company’s inaugural drug candidate is CS-6.

About CS-6

CS-6 belongs to a new class of drug candidates intended to treat most forms of

cancer in a comprehensive manner, targeting both cancer cells and their

progenitors, the cancer stem cells. CS-6 shows broad anti-proliferative and

cytotoxic activity against human cancer cells, with particular activity against

human glioblastoma cells. CS-6 also has been designed deliberately to meet the

major known criteria for crossing the blood-brain barrier, and for that reason is

being developed as a first-line for the treatment of glioblastoma multiforme, the

main form of primary brain cancer.

Further information

Contact Dr Graham Kelly, Chief Executive Officer.

T: (61 2) 9878 0088

M: (61) 0459 200 095

E: Graham.Kelly@novogen.com

Further information is available on the Company’s web site, www.novogen.com